# to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

> **NCT05162937** · PHASE2 · COMPLETED · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 160 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** IL-17A antibody

## Key facts

- **NCT ID:** NCT05162937
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-11-02
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162937, "to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05162937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*